trihexyphenidyl has been researched along with Chronic Disease in 15 studies
Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Plasma chlorpromazine (CPZ) levels of 50 psychotic inpatients were measured by gas liquid chromatography; the clinical progress of 29 of these patients with acute psychoses was also assessed." | 3.65 | Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels. ( Lasagna, L; Nasrallah, H; Rivera-Calimlim, L; Strauss, J, 1976) |
| "Twenty-one chronic schizophrenics were stabilized with chlorpromazine therapy at their therapeutic dosage for one month." | 2.65 | Effect of antiparkinsonian medication on plasma levels of chlorpromazine. ( Bark, N; Cooper, TB; Lee, JH; Simpson, GM; Sud, I, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (93.33) | 18.7374 |
| 1990's | 1 (6.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Manos, N | 2 |
| Gkiouzepas, J | 2 |
| Logothetis, J | 1 |
| Kua, EH | 1 |
| Ang, PC | 1 |
| Siew, HC | 1 |
| Irwin, GE | 1 |
| Simon, JE | 1 |
| Simpson, GM | 1 |
| Cooper, TB | 1 |
| Bark, N | 1 |
| Sud, I | 1 |
| Lee, JH | 1 |
| Domino, EF | 1 |
| Ni, L | 1 |
| Rivera-Calimlim, L | 1 |
| Nasrallah, H | 1 |
| Strauss, J | 1 |
| Lasagna, L | 1 |
| Garelis, E | 1 |
| Gillin, JC | 1 |
| Wyatt, RJ | 1 |
| Neff, N | 1 |
| Rinieris, P | 1 |
| Hatzimanolis, J | 1 |
| Markianos, M | 1 |
| Stefanis, C | 1 |
| Gol'dovskaia, IL | 1 |
| Klett, CJ | 1 |
| Caffey, E | 1 |
| Singh, MM | 1 |
| Smith, JM | 1 |
| Turek, I | 1 |
| Kurland, AA | 1 |
| Hanlon, TE | 1 |
| Bohm, M | 1 |
| Yaryura-Tobias, JA | 1 |
| Wolpert, A | 1 |
| Dana, L | 1 |
| Merlis, S | 1 |
| Gjerris, F | 1 |
4 trials available for trihexyphenidyl and Chronic Disease
| Article | Year |
|---|---|
Discontinuing antiparkinson medication in chronic schizophrenics. At what cost to the patient?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chronic Disease; Clinical Trials as Topic; Double-Blin | 1981 |
Effect of antiparkinsonian medication on plasma levels of chlorpromazine.
Topics: Chlorpromazine; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Mal | 1980 |
Evaluating the long-term need for antiparkinson drugs by chronic schizophrenics.
Topics: 1-Propanol; Adult; Antiparkinson Agents; Basal Ganglia Diseases; Benztropine; Biperiden; Chronic Dis | 1972 |
Sleeplessness in acute and chronic schizophrenia--response to haloperidol and anti-parkinsonism agents.
Topics: Acute Disease; Adult; Antiparkinson Agents; Arousal; Benztropine; Chronic Disease; Clinical Trials a | 1973 |
11 other studies available for trihexyphenidyl and Chronic Disease
| Article | Year |
|---|---|
The need for continuous use of antiparkinsonian medication with chronic schizophrenic patients receiving long-term neuroleptic therapy.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Combination; Dyskin | 1981 |
Tardive dyskinesia in chronic schizophrenic inpatients.
Topics: Adult; Antipsychotic Agents; Chronic Disease; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle | 1982 |
Neuroleptic malignant syndrome.
Topics: Basal Ganglia Diseases; Chronic Disease; Diagnosis, Differential; Dibenzoxazepines; Dose-Response Re | 1984 |
Trihexyphenidyl potentiation of L-DOPA: reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys.
Topics: Animals; Antiparkinson Agents; Chronic Disease; Dopamine Agents; Dose-Response Relationship, Drug; D | 1998 |
Clinical response and plasma levels: effect of dose, dosage schedules, and drug interactions on plasma chlorpromazine levels.
Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Brief Psychiatric Rating Scale; Chlorproma | 1976 |
Elevated blood serotonin concentrations in unmediated chronic schizophrenic patients: a preliminary study.
Topics: Adolescent; Adult; Amitriptyline; Antipsychotic Agents; Benztropine; Blood Cell Count; Blood Platele | 1975 |
Effects of 4 weeks treatment with chlorpromazine and/or trihexyphenidyl on the pituitary-gonadal axis in male paranoid schizophrenics.
Topics: Adult; Chlorpromazine; Chronic Disease; Drug Therapy, Combination; Gonadal Steroid Hormones; Humans; | 1988 |
[The possibilities and limitations of psychotropic drug therapy for patients with glaucoma].
Topics: Aged; Alcoholism; Amitriptyline; Antidepressive Agents; Bipolar Disorder; Chronic Disease; Dementia; | 1974 |
Tardive dyskinesia: its relation to neuroleptic and antiparkinson drugs.
Topics: Aged; Chronic Disease; Female; Humans; Intellectual Disability; Male; Middle Aged; Movement Disorder | 1972 |
Action of L-Dopa in drug induced extrapyramidalism.
Topics: Adult; Chlorpromazine; Chronic Disease; Dihydroxyphenylalanine; Extrapyramidal Tracts; Female; Human | 1970 |
Transitory procaine-induced Parkinsonism.
Topics: Chronic Disease; Dihydroxyphenylalanine; Female; Humans; Middle Aged; Parkinson Disease; Parkinson D | 1971 |